Date: 2016-10-03
Type of information: Financing round
Company: Carrick Therapeutics (Ireland)
Investors: ARCH Venture Partners (USA - IL) Cambridge Enterprise Seed Funds (UK) Cambridge Innovation Capital (UK) Evotec (Germany) Google Ventures (USA - CA) Lightstone Ventures (USA - CA) Woodford Investment Management (UK)
Amount: $95 million (€84.7 million)
Funding type: financing round
Planned used: Carrick Therapeutics is a new start-up dedicated to cancer treatment. Its research and development teams are located in Dublin, Ireland, and Oxford, UK. Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance and tailored to an individual patient's tumour. Chief Executive of Carrick Therapeutics is Dr. Elaine Sullivan, a former Vice President for research and development functions at both US pharmaceutical giant Eli Lilly and UK medical leader AstraZeneca. "One of our founding scientific programmes is derived from the laboratory of Professor Steve Jackson FRS FMedSci, who is also a member of our scientific advisory board, said Elaine Sullivan. Professor Jackson is the University of Cambridge and Cancer Research UK Professor of Biology, as well as Head of Cancer Research UK Laboratories. He pioneered work resulting in a new medicine, known as olaparib/Lynparza™, to treat ovarian cancer based on the molecular profile of the patient." Carrick Therapeutics is working on three innovative scientific programmes, and is looking to expand its portfolio through academic and pharmaceutical partnerships. The company's worldwide network of collaborating cancer experts includes the world's leading cancer research charity, Cancer Research UK, and pioneering researchers from several of the world's top universities, including Cambridge, Imperial College London and Oxford. Carrick Therapeutics has assembled a team of internationally recognised clinicians and scientists for the company's scientific advisory board (SAB), which is chaired by Sir John Bell (Regius Professor of Medicine, University of Oxford). The SAB comprises: Prof. Chas Bountra (Oxford), Prof. Johann DeBono (London), Prof. William Gallagher (Dublin), Prof. Steve Jackson (Cambridge), Prof. Peter Johnson (Southampton), Prof. David Kerr (Oxford), Prof. Michael O'Dwyer (Galway), Dr. Anthony Quinn (Boston), and Prof. John Robertson (Nottingham).
Others: * On October 3, 2016, Carrick Therapeutics announced having secured $95 million in funding. The funding round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, GV (Google Ventures), and Lightstone Ventures.
Evotec will invest up to $ 6 m towards Carrick’s funding round.
In conjunction with the funding, Steven Gillis and Paul Thurk, ARCH Venture Partners, and Jason Lettmann, Lightstone Ventures, join CEO Elaine Sullivan on the Carrick board of directors.
Therapeutic area: Cancer - Oncology
